Work

Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells

Year: 2024

Type: article

Abstract: 19CAR-T cell-driven B cell aplasia. Thus, we demonstrate that genome engineering enables immunosuppressant treatment to improve the therapeutic potential of universal donor-derived CAR-T cells.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2024.06.022

Authors: Colby R. Maldini, Angelica C. Messana, Paula B. Bendet, Adam J. Camblin, Faith M. Musenge, Moriah L. White, Joseph J. Rocha, Lindsey J. Coholan, Cisem Karaca, Frederick Li, Bo Yan, Vladimir D. Vrbanac, Emily Marte, Daniel T. Claiborne, Christian L. Boutwell, Todd M. Allen

Institutions: Beam Therapeutics (United States), Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology, The Wistar Institute, Harvard University, Massachusetts General Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,900

Funders: Ragon Institute of MGH, MIT and Harvard, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases

Awards: G3687201263, G9000200023, Consolidated Basic Cancer Research Program, Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection

OpenAlex ID: W4402111331

FWCI: 2.438

Cites: 86

Cited by: 16

Related to: 10